Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02653170 · ClinicalTrials.gov registry record · NA
Michigan Stroke Transitions Trial
A NA study, sponsored by Michigan State University.
- Completed
- Registry status
- NA
- Development phase
- 320
- Enrollment target
NCT02653170 is a NA study that has completed, run by Michigan State University. The registered enrollment target is 320 participants.
The verdict
NCT02653170, a NA study, has completed, sponsored by Michigan State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 320 participants
- Enrollment target
Study Summary
The Michigan Stroke Transitions Trial (MISTT) is a patient-centered randomized control trial that aims to improve the experience of stroke patients after they return home. The MISTT study will test the effect of two complementary interventions against usual care. The two interventions include: a) Stroke Case Managers (SCMs) who are trained social workers, and b) an online informational website or portal. The 12 week intervention period begins when the stroke patient returns home from the hospital or rehab facility. The SCMs will conduct at least 2 home visits with the patient (one within 3-4 days and one around 30 days) along with weekly follow-up telephone calls. Supplemental home visits will be used as necessary over the 12 week period. At the first home visit the social workers will conduct a comprehensive in-home assessment and link patients and caregivers to local resources as necessary. Patients also assigned to the website will have access to a patient-centered online information and support resource called the Virtual Stroke Support Portal (VSSP). The investigators hypothesize that this personalized case management program will reduce patient and caregiver needs, improve quality of life, and decrease caregiver stress. The MISTT study will enroll 315 acute stroke patients discharged from 3 Michigan hospitals and will be completed by the end of 2017.
Interventions
- OTHER SCM
- OTHER SCM and VSSP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2016-01 |
| Est. Completion | 2017-11-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02653170
The ClinicalTrials.gov registry entry for NCT02653170 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Michigan State University, which has 120 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SCM is the first listed.
NCT02653170 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02653170 about?
NCT02653170 is a clinical study titled "Michigan Stroke Transitions Trial". The Michigan Stroke Transitions Trial (MISTT) is a patient-centered randomized control trial that aims to improve the experience of stroke patients after they return home. The MISTT study will test the effect of two complementary interventions against usual care. The two interventions include: a) St...
What is the current status of trial NCT02653170?
This trial is currently completed. It is a NA study. The enrollment target is 320 participants. The study started on 2016-01. Estimated completion is 2017-11-30.
What interventions are being tested in trial NCT02653170?
The interventions under investigation include: SCM (OTHER), SCM and VSSP (OTHER).
Who is sponsoring clinical trial NCT02653170?
This trial is sponsored by Michigan State University, which has 120 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.